GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CFO Kevin Feeley sold 402 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares of the company’s stock, valued at $454,212.20. This represents a 7.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Kevin Feeley also recently made the following trade(s):
- On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79.
- On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total value of $87,331.84.
- On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.
- On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
- On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.
GeneDx Trading Down 4.1 %
NASDAQ WGS traded down $4.01 during trading hours on Monday, reaching $94.46. The company’s stock had a trading volume of 668,407 shares, compared to its average volume of 612,654. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a market cap of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91. The firm has a fifty day simple moving average of $84.69 and a 200-day simple moving average of $70.37.
Institutional Investors Weigh In On GeneDx
Institutional investors have recently made changes to their positions in the stock. William Blair Investment Management LLC bought a new position in shares of GeneDx during the fourth quarter worth about $51,496,000. Lord Abbett & CO. LLC acquired a new stake in GeneDx during the 4th quarter valued at approximately $48,458,000. Summit Partners Public Asset Management LLC raised its holdings in GeneDx by 336.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after purchasing an additional 582,619 shares during the last quarter. Science & Technology Partners L.P. acquired a new position in shares of GeneDx in the 4th quarter worth approximately $30,821,000. Finally, Fred Alger Management LLC bought a new stake in shares of GeneDx in the 3rd quarter valued at $16,731,000. Institutional investors own 61.72% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on WGS. The Goldman Sachs Group boosted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $72.33.
Get Our Latest Analysis on GeneDx
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
- Five stocks we like better than GeneDx
- Insider Trades May Not Tell You What You Think
- Can TikTok Stock Picks Really Make You Rich?
- Compound Interest and Why It Matters When Investing
- The “Quality” Rotation: Back to Basics Investing
- Technology Stocks Explained: Here’s What to Know About Tech
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.